MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors. Amrane K, Le Noac'h P, Hemon P, Abgral R, et al. Melanoma Res 2025 Feb 12. doi: 10.1097/CMR.0000000000001022.

Read + Share

Amedeo Smart

Independent Medical Education

Amrane K, Le Noac'h P, Hemon P, Abgral R, et al. MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors. Melanoma Res 2025 Feb 12. doi: 10.1097/CMR.0000000000001022.
PMID: 39945603